Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types 1 , 2 , 3 , 4 , 5 . One …

The spondyloarthropathies are a group of rheumatic diseases that are associated with
inflammation at anatomically distal sites, particularly the tendon-bone attachments (entheses) and …

Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity,
and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with …

Anti-PD-1 immune checkpoint blockers can induce sustained clinical responses in cancer
but how they function in vivo remains incompletely understood. Here, we combined intravital …

Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide
important prognostic information in diverse solid tumor types, and may also be of value in …

The C-type lectin-like receptor CD161, which has recently been described to promote T cell
expansion, is expressed on a discrete subset of human CD4 T cells. The function of such …

BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer,
but many patients do not respond to treatment. The identification of robust biomarkers that …

Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T
cells. Although successful in treatment of hematologic malignancies, CAR T cells are …

We explored the association between liver metastases, tumor CD8 + T-cell count, and
response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, …